Premium
Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers
Author(s) -
Murray L. Barclay,
Evan J. Begg,
Richard Robson,
William A. Peters,
John W. Ketelbey
Publication year - 1999
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1999.00595.x
Subject(s) - lansoprazole , pharmacokinetics , medicine , gastroenterology , area under the curve , confidence interval , pharmacology , omeprazole
Aim : To compare the pharmacokinetics of lansoprazole in patients with reflux oesophagitis and in healthy volunteers, after a single dose and at steady‐state. Patients and methods : A 30 mg dose of lansoprazole was administered orally daily for 7 days in eight healthy male volunteers aged 21–24 years, and in 16 patients aged 29–65 years with grade 2 or 3 reflux oesophagitis. The pharmacokinetics were assessed over the 24 h dose interval following the first dose and again after the 7th dose. Results : Within both the patient and volunteers groups, there were no significant differences between day 1 and day 7 in any of the pharmacokinetic parameters including maximum concentration ( C max ), area under the concentration–time curve ( AUC ), and terminal half‐life of elimination ( t ½ ). However, on both days 1 and 7, values were significantly higher in the patients than in the healthy volunteers. On day 7, C max was 1343 ng/mL in patients compared with 765 ng/mL in healthy volunteers, AUC was 3458 ng.h/mL vs. 1350 ng.h/mL and t ½ was 1.62 h vs. 0.90 h. Conclusion : The differences in results for the pharmacokinetics reflect reduced lansoprazole clearance in the patient group. Other research has not found a difference in pharmacokinetics when comparing healthy volunteers with patients with acid‐related disorders. The difference in lansoprazole clearance in this study may be related to a variety of factors that are different in patients compared with young normal volunteers, such as age, gender, other drugs, and reduced general well‐being.